AxoGen Competitors

InMode (NASDAQ:INMD) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

35.7% of InMode shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 6.9% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares InMode and AxoGen's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares InMode and AxoGen's revenue, earnings per share (EPS) and valuation.

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for InMode and AxoGen, as provided by MarketBeat.com.

InMode currently has a consensus target price of $71.50, suggesting a potential downside of 11.39%. AxoGen has a consensus target price of $23.75, suggesting a potential upside of 18.39%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than InMode.

Volatility & Risk

InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Summary

InMode beats AxoGen on 11 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 84.6% of Outset Medical shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares AxoGen and Outset Medical's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares AxoGen and Outset Medical's revenue, earnings per share and valuation.

Outset Medical has lower revenue, but higher earnings than AxoGen.

Analyst Recommendations

This is a summary of current ratings and target prices for AxoGen and Outset Medical, as reported by MarketBeat.

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. Outset Medical has a consensus price target of $56.50, suggesting a potential downside of 3.14%. Given AxoGen's stronger consensus rating and higher possible upside, equities research analysts clearly believe AxoGen is more favorable than Outset Medical.

Summary

Outset Medical beats AxoGen on 5 of the 9 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Comparatively, 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares AxoGen and BioLife Solutions' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares AxoGen and BioLife Solutions' revenue, earnings per share and valuation.

BioLife Solutions has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for AxoGen and BioLife Solutions, as reported by MarketBeat.

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. BioLife Solutions has a consensus price target of $46.6667, suggesting a potential upside of 29.63%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than AxoGen.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Summary

BioLife Solutions beats AxoGen on 11 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Profitability

This table compares AxoGen and Natus Medical's net margins, return on equity and return on assets.

Insider and Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 89.7% of Natus Medical shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Comparatively, 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares AxoGen and Natus Medical's revenue, earnings per share and valuation.

Natus Medical has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for AxoGen and Natus Medical, as reported by MarketBeat.

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. Given AxoGen's stronger consensus rating and higher possible upside, equities research analysts clearly believe AxoGen is more favorable than Natus Medical.

Summary

Natus Medical beats AxoGen on 8 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares AxoGen and TransMedics Group's net margins, return on equity and return on assets.

Insider & Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 76.7% of TransMedics Group shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Comparatively, 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares AxoGen and TransMedics Group's top-line revenue, earnings per share and valuation.

AxoGen has higher revenue and earnings than TransMedics Group. AxoGen is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AxoGen and TransMedics Group, as reported by MarketBeat.com.

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. TransMedics Group has a consensus price target of $44.20, suggesting a potential upside of 39.17%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than AxoGen.

Summary

AxoGen beats TransMedics Group on 7 of the 12 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares AxoGen and ViewRay's net margins, return on equity and return on assets.

Insider & Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 83.0% of ViewRay shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Comparatively, 15.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares AxoGen and ViewRay's top-line revenue, earnings per share and valuation.

AxoGen has higher revenue and earnings than ViewRay. AxoGen is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AxoGen and ViewRay, as reported by MarketBeat.com.

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. ViewRay has a consensus price target of $4.50, suggesting a potential upside of 4.90%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than ViewRay.

Summary

AxoGen beats ViewRay on 9 of the 14 factors compared between the two stocks.